The Experts below are selected from a list of 6189 Experts worldwide ranked by ideXlab platform
Caterina Vivaldi - One of the best experts on this subject based on the ideXlab platform.
-
multivariate prognostic factors analysis for second line chemotherapy in advanced Biliary Tract Cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina VivaldiAbstract:Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer
-
Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina VivaldiAbstract:Background: The role of second-line chemotherapy (CT) is not established in advanced Biliary Tract Cancer (aBTC). We investigated the outcome of aBTC patients treated with second-line CT and devised a prognostic model. Methods: Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS) was investigated by multivariable Cox models. Results: The following parameters resulted independently associated with longer OS: Eastern Cooperative Oncology Group performance status of 0 ( P
Ann W Hsing - One of the best experts on this subject based on the ideXlab platform.
-
diet and Biliary Tract Cancer risk in shanghai china
PLOS ONE, 2017Co-Authors: Shakira M Nelson, Leticia Nogueira, Ming Chang Shen, Bingsheng Wang, Asif Rashid, Ann W Hsing, Jill KoshiolAbstract:Trends in Biliary Tract Cancer incidence rates have increased in Shanghai, China. These trends have coincided with economic and developmental growth, as well as a shift in dietary patterns to a more Westernized diet. To examine the effect of dietary changes on incident disease, we evaluated associations between diet and Biliary Tract Cancers amongst men and women from a population-based case-control study in Shanghai, China. Biliary Tract Cancer cases were recruited from 42 collaborating hospitals in urban Shanghai, and population-based controls were randomly selected from the Shanghai Household Registry. Food frequency questionnaire data were available for 225 gallbladder, 190 extrahepatic bile duct, and 68 ampulla of Vater Cancer cases. A total of 39 food groups were created and examined for associations with Biliary Tract Cancer. Interestingly, only four food groups demonstrated a suggested association with gallbladder, extrahepatic bile duct, or ampulla of Vater Cancers. The allium food group, consisting of onions, garlic, and shallots showed an inverse association with gallbladder Cancer (OR: 0.81, 95% CI: 0.68–0.97). Similar trends were seen in the food group containing seaweed and kelp (OR: 0.79, 95% CI: 0.67–0.96). In contrast, both preserved vegetables and salted meats food groups showed positive associations with gallbladder Cancer (OR:1.27, 95% CI: 1.06–1.52; OR: 1.18, 95% CI: 1.02–1.37, respectively). Each of these four food groups showed similar trends for extrahepatic bile duct and ampulla of Vater Cancers. The results of our analysis suggest intake of foods with greater anti-inflammatory properties may play a role in decreasing the risk of Biliary Tract Cancers. Future studies should be done to better understand effects of cultural changes on diet, and to further examine the impact diet and inflammation have on Biliary Tract Cancer incidence.
-
metabolic syndrome and insulin resistance in relation to Biliary Tract Cancer and stone risks a population based study in shanghai china
British Journal of Cancer, 2011Co-Authors: Fatma M Shebl, Ming Chang Shen, Bingsheng Wang, Asif Rashid, Gabriella Andreotti, Tamra E Meyer, Kai Yu, Bai He Zhang, Frank Z Stanczyk, Ann W HsingAbstract:Metabolic syndrome and insulin resistance in relation to Biliary Tract Cancer and stone risks: a population-based study in Shanghai, China
-
chronic typhoid infection and the risk of Biliary Tract Cancer and stones in shanghai china
Infectious Agents and Cancer, 2011Co-Authors: Mahboobeh Safaeian, Asif Rashid, Lori C Sakoda, Sabah M Quraishi, Bing Shen Wang, Jinbo Chen, James Pruckler, Eric D Mintz, Ann W HsingAbstract:Previous studies have shown a positive association between chronic typhoid carriage and Biliary Cancers. We compared serum Salmonella enterica serovar Typhi antibody titers between Biliary Tract Cancer cases, Biliary stone cases without evidence of Cancer, and healthy subjects in a large population-based case-control study in Shanghai, China. Participants included 627 newly diagnosed primary Biliary Tract Cancer patients; 1,037 Biliary stone cases (774 gallbladder and 263 bile-duct) and 959 healthy subjects without a history of Cancer, randomly selected from the Shanghai Resident Registry. Overall only 6/2,293 (0.26%) were Typhi positive. The prevalence of Typhi was 1/457 (0.22%), 4/977 (0.41%), and 1/859 (0.12%) among Cancer cases, Biliary-stone cases, and population controls, respectively. We did not find an association between Typhi and Biliary Cancer in Shanghai, due to the very low prevalence of chronic carriers in this population. The low seroprevalence of S. Typhi in Shanghai is unlikely to explain the high incidence of Biliary Cancers in this population.
-
family history of gallstones and the risk of Biliary Tract Cancer and gallstones a population based study in shanghai china
International Journal of Cancer, 2007Co-Authors: Ann W Hsing, Ming Chang Shen, Asif Rashid, Jinbo Chen, Gabriella Andreotti, Jie Deng, Alisa M Goldstein, Joseph F. FraumeniAbstract:Biliary Tract Cancers, encompassing tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater, are relatively uncommon malignancies in most parts of the world (1). The highest incidence rates have been observed among Native Americans and Hispanics living in the Southwestern United States and among some populations in Central and South America, Eastern Europe, and certain parts of Asia (1,2). Between 1972 to 1994, the incidence rates for Biliary Tract Cancer rose more rapidly than those for any other malignancy in Shanghai, China, with increases of 119% among men and 124% among women (3). The increases in incidence were seen for all three Biliary Tract subsites in all age groups. Gallstones are the most important risk factor for Biliary Tract Cancers (1,4), especially for gallbladder Cancer patients in whom 60-80% have a history of gallstones (1,5,6). Both gallstones and gallbladder Cancer occur more frequently among women and older persons. Ethnic and familial predisposition suggests the role of genetic predisposition or shared lifestyle and metabolic factors, including obesity, insulin resistance, or high-fat, high-caloric diet (1,7-9). Familial aggregation of gallstones has been reported in several studies (10-12), but only one assessed the role of family history of gallstones in Biliary Tract Cancer etiology. A case-control study of gallbladder Cancer in Bolivia and Mexico reported that family history of gallstones was associated with a 3.6-fold risk of gallbladder Cancer (13). The mechanisms are unclear, but it is possible that some yet unidentified susceptibility mechanism may further elevate the risk of Biliary Tract Cancer associated with stones. To investigate the rapid rise in incidence rates of Biliary Tract Cancers in Shanghai, we conducted a large population-based study in Shanghai between 1997 and 2001. In this report, we examined whether a family history of gallstones is an independent risk factor for Biliary Tract Cancer and whether it augments the risk associated with the presence of gallstones.
-
Biliary Tract Cancer and stones in relation to chronic liver conditions a population based study in shanghai china
International Journal of Cancer, 2007Co-Authors: Ann W Hsing, Ming Chang Shen, Bingsheng Wang, Lori C Sakoda, Jinbo Chen, Katherine A Mcglynn, Shelley Niwa, Mingdong Zhang, Bai He ZhangAbstract:Biliary Tract Cancers are relatively rare but fatal tumors. Apart from a close link with gallstones and cholangitis, risk factors for Biliary Tract Cancer are obscure. Chronic liver conditions, including liver cirrhosis, have been linked to a higher risk of Biliary Tract Cancer. In a population-based case-control study conducted in Shanghai, China, we investigated the relationships of a history of chronic hepatitis and liver cirrhosis as well as a family history of liver Cancer with Biliary Tract Cancer risk. The study included 627 patients with Biliary Tract Cancers (368 gallbladder, 191 bile duct and 68 ampulla of Vater), 1,037 patients with Biliary stones (774 gallbladder stones and 263 bile duct stones) and 959 healthy subjects randomly selected from the population. Bile duct Cancer was associated with self-reports of chronic liver conditions, including a history of chronic hepatitis (OR = 2.0, 95% CI 0.9–4.4), liver cirrhosis (OR = 4.7, 95% CI 1.9–11.7) and a family history of primary liver Cancer (OR = 2.0, 95% CI 1.0–3.9). The excess risk persisted after adjustment for gallstones and were more pronounced among subjects without gallstones (OR = 5.0, 95% CI 1.3–20.0 and OR = 4.9, 95% 2.0–12.2, respectively). History of liver conditions was also associated with an excess of Biliary stones (OR = 1.9, 95% CI 1.2–3.0). No association was found for Cancers of the gallbladder and ampulla of Vater. A history of chronic hepatitis and cirrhosis may be risk factors for extraheptic bile duct Cancer. Given that chronic infection with hepatitis B virus (HBV) is the most common cause of liver disease in China, serologic markers of HBV need to be measured in future studies to examine the link between HBV and bile duct Cancer. © 2007 Wiley-Liss, Inc.
Takashi Sasaki - One of the best experts on this subject based on the ideXlab platform.
-
current status of chemotherapy for the treatment of advanced Biliary Tract Cancer
The Korean Journal of Internal Medicine, 2013Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko KoikeAbstract:Chemotherapy is indispensable for the treatment of advanced Biliary Tract Cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine and oxaliplatin combination therapy) have become the standard of care for advanced Biliary Tract Cancer. Oral fluoropyrimidines have also been shown to have good antitumor effects. Gemcitabine, platinum compounds, and oral fluoropyrimidines are now considered key drugs for the treatment of advanced Biliary Tract Cancer. Several clinical trials using molecular targeted agents are also ongoing. Combination therapy using cytotoxic agents and molecular-targeted agents has been evaluated widely. However, reports regarding second-line chemotherapy remain limited, and it has not yet been clarified whether second-line chemotherapy can improve the prognosis of advanced Biliary Tract Cancer. Thus, there is an urgent need to establish second-line standard chemotherapy treatment for advanced Biliary Tract Cancer. Several problems exist when assessing the results of previous reports concerning advanced Biliary Tract Cancer. In the present review, the current status of the treatment of advanced Biliary Tract Cancer is summarized, and several associated problems are indicated. These problems should be solved to achieve more sophisticated treatment of advanced Biliary Tract Cancer.
-
a randomized phase ii study of gemcitabine and s 1 combination therapy versus gemcitabine monotherapy for advanced Biliary Tract Cancer
Cancer Chemotherapy and Pharmacology, 2013Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Naoki Sasahira, Hirofumi Kogure, Nobuo Toda, Ichiro Yasuda, Keiji Hanada, Hiroyuki Maguchi, Hideki KamadaAbstract:Purpose In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced Biliary Tract Cancer.
-
Improvement of prognosis for unresectable Biliary Tract Cancer
World Journal of Gastroenterology, 2013Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Naminatsu Takahara, Naoki Sasahira, Hirofumi Kogure, Suguru Mizuno, Hiroshi Yagioka, Natsuyo YamamotoAbstract:CONCLUSION: The prognosis of unresectable Biliary Tract Cancer has improved recently. Using three effective drugs (gemcitabine, platinum analogs, and fluoropyrimidine) may improve the prognosis of this Cancer.
-
prognostic factors in patients with advanced Biliary Tract Cancer receiving chemotherapy
Cancer Chemotherapy and Pharmacology, 2011Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Hirofumi Kogure, Suguru Mizuno, Hiroshi Yagioka, Osamu Togawa, Keisuke Yamamoto, Yoko Yashima, Kazumichi KawakuboAbstract:Purpose Prognostic factors for patients with advanced Biliary Tract Cancer receiving chemotherapy are presently not well established. Gallbladder Cancer and intra-hepatic cholangiocarcinoma are previously reported prognostic factors of poor prognosis; however, tumor volume has not been analyzed in these previous reports.
-
multicenter phase ii study of gemcitabine and s 1 combination chemotherapy in patients with advanced Biliary Tract Cancer
Cancer Chemotherapy and Pharmacology, 2010Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Hirofumi Kogure, Osamu Togawa, Nobuo Toda, Ichiro Yasuda, Osamu Hasebe, Iruru Maetani, Naoki SasahiraAbstract:Purpose To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced Biliary Tract Cancer.
Takuji Okusaka - One of the best experts on this subject based on the ideXlab platform.
-
Chemotherapy for Biliary Tract Cancer in Japan.
Seminars in oncology, 2020Co-Authors: Takuji OkusakaAbstract:The incidence of Biliary Tract Cancer has increased markedly in Japan over the past several decades and ranks as the sixth leading cause of Cancer death. Currently, there is no standard chemotherapy for Biliary Tract Cancer. Early phase investigation of cisplatin and cisplatin/epirubicin/5-fluorouracil yielded disappointing results in this setting. Gemcitabine is currently approved for use in the treatment of non-small cell lung Cancer and pancreatic Cancer in Japan. Based on the single-agent activity of gemcitabine in Biliary Tract Cancer in other locales combined with the drug's established safety profile, gemcitabine is currently being evaluated as single-agent therapy in the treatment of advanced Biliary Tract Cancer patients in Japan.
-
New developments in systemic therapy for advanced Biliary Tract Cancer.
Japanese Journal of Clinical Oncology, 2018Co-Authors: Chigusa Morizane, Takuji Okusaka, Makoto Ueno, Masafumi Ikeda, Hiroshi Ishii, Junji FuruseAbstract:Biliary Tract Cancer, carcinoma of the extrahepatic bile ducts, carcinoma of the gall bladder, ampullary carcinoma and intrahepatic cholangiocarcinoma are often identified at an advanced stage and have poor prognoses. Although effective chemotherapy regimens are needed, their development remains unsatisfactory. From the results of a phase III clinical trial (ABC-02 trial), gemcitabine plus cisplatin is the standard first-line chemotherapeutic regimen for advanced Biliary Tract Cancer. A phase III trial of gemcitabine plus cisplatin vs. gemcitabine plus S-1 therapy (FUGA-BT) demonstrated the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin. A phase III trial of gemcitabine plus cisplatin vs. gemcitabine plus cisplatin plus S-1 (MITSUBA) was conducted, and the report on the results of the final analysis is being awaited. A standard second-line chemotherapeutic regimen has not yet been established. Fluoropyrimidines are frequently used in clinical practice. Despite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced Biliary Tract Cancer. Next-generation sequencing shows great promise by allowing rapid mutational analysis of multiple genes in human Cancers, and atTractive driver genetic alterations have been reported in Biliary Tract Cancer. FGFR2 fusion gene, mutations of IDH1/2, BRAF, BRCA1/2, ATM, PIK3CA and overexpression of c-MET and HER2/neu are reported relatively frequently and are interesting targets. Therefore, future development in precision medicine utilizing next-generation sequencing is expected. Although the efficacy of immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1 and anti-CTLA4 antibodies, remains unknown at present, basic data and results of ongoing clinical trials are anticipated.
-
prognostic factors for progression free and overall survival in advanced Biliary Tract Cancer
Annals of Oncology, 2016Co-Authors: J Bridgewater, Takuji Okusaka, Lars Henrik Jensen, Andre Lopes, Harpreet Wasan, D Malka, Jennifer J Knox, Dorothea Wagner, David Cunningham, J ShannonAbstract:ABSTract Background Biliary Tract Cancer is an uncommon Cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease. Methods Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using the independent international dataset. Results A total of 410 patients were included from the ABC-02 study and 753 from the international dataset. An overall survival (OS) and progression-free survival (PFS) Cox model was derived from the ABC-02 study. White blood cells, haemoglobin, disease status, bilirubin, neutrophils, gender, and performance status were considered prognostic for survival (all with P Conclusion These data propose a set of prognostic criteria for outcome in advanced Biliary Tract Cancer derived from the ABC-02 study that are validated in an international dataset. Although these findings establish the benchmark for the prognostic evaluation of patients with ABC and confirm the value of longheld clinical observations, the ability of the model to correctly predict prognosis is limited and needs to be improved through identification of additional clinical and molecular markers.
-
Targeted Therapy for Biliary Tract Cancer
Cancers, 2011Co-Authors: Junji Furuse, Takuji OkusakaAbstract:It is necessary to establish effective chemotherapy to improve the survival of patients with Biliary Tract Cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable Biliary Tract Cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against Biliary Tract Cancer. Although some targeted agents have been investigated as monotherapy for first-line chemotherapy, none were found to exert satisfactory efficacy. On the other hand, monoclonal antibodies such as bevacizumab and cetuximab have also been investigated in combination with a gemcitabine-based regimen and have been demonstrated to show promising activity. Furthermore, clinical trials using new targeted agents for Biliary Tract Cancer are also proposed. This Cancer is a relatively rare and heterogeneous tumor consisting of cholangiocarcinoma and gallbladder carcinoma. Therefore, a large randomized clinical trial is necessary to confirm the efficacy of chemotherapy, and international collaboration is important.
-
gemcitabine alone or in combination with cisplatin in patients with Biliary Tract Cancer a comparative multicentre study in japan
British Journal of Cancer, 2010Co-Authors: Takuji Okusaka, Masato Nagino, Akihiro Funakoshi, Shinichi Ohkawa, Kohei Nakachi, Akira Fukutomi, Nobumasa Mizuno, Satoshi Kondo, S Nagaoka, J FunaiAbstract:Gemcitabine alone or in combination with cisplatin in patients with Biliary Tract Cancer: a comparative multicentre study in Japan
Lorenzo Fornaro - One of the best experts on this subject based on the ideXlab platform.
-
multivariate prognostic factors analysis for second line chemotherapy in advanced Biliary Tract Cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina VivaldiAbstract:Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer
-
Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer
British Journal of Cancer, 2014Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina VivaldiAbstract:Background: The role of second-line chemotherapy (CT) is not established in advanced Biliary Tract Cancer (aBTC). We investigated the outcome of aBTC patients treated with second-line CT and devised a prognostic model. Methods: Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS) was investigated by multivariable Cox models. Results: The following parameters resulted independently associated with longer OS: Eastern Cooperative Oncology Group performance status of 0 ( P